🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Hepatocellular Carcinoma Resectable

Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence NCT06954116Phase 21 site📍 Wuhan Tongji Hospital · Tests: Iparomlimab and Tuvonralimab (QL1706), Partial hepatectomy Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC NCT06041477Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Concurrent Lenvatinib, Concurrent PD-1 antibody, Sequential L… Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study NCT07305428NA1 site📍 Hong Kong The University of Hong Kong · Tests: Stereotactic Body Radiation Therapy followed by Immunotherapy Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma NCT06133062Phase 21 site📍 Taoyuan City Chang Gung Memorial Hospital · Tests: Atezolizumab, Bevacizumab, Proton radiotherapy THIO and Cadonilimab in Resectable Hepatocellular Carcinoma NCT07446257EARLY Phase 11 site📍 Dallas University of Texas Southwestern Medical Center · Tests: ateganosine, Cadonilimab Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) NCT05185739Phase 211 sites📍 Birmingham📍 Cambridge📍 Edinburgh University College, London · Tests: Pembrolizumab, Lenvatinib, Pembrolizumab and Lenvatinib Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC NCT06397222Phase 21 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Sin-Bev-SIRT Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT NCT06904183Phase 21 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: LEN+SIN+DEB-TACE+HAIC, LEN+SIN+DEB-TACE FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma NCT07012798Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Durvalumab, Bevacizumab, HAIC of FOLFOX Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642n/a3 sites📍 Phoenix📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Tissue Collection Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma NCT07324824Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: sintilimab combined with bevacizumab biosimilar DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC NCT06397235Phase 21 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: DEB-TACE+HAIC, DEB-TACE Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC NCT07801287Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Iparomlimab/Tuvonralimab plus SBRT and Lenvatinib Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model NCT06420440Phase 22 sites📍 Xiangyang📍 Jinan Chen Xiaoping · Tests: Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab, Liver resection, Tislelizumab Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC NCT05608213Phase 31 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Lenvatinib Plus I-125 Seed Brachytherapy, Lenvatinib Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma NCT06582017Phase 111 sites📍 Los Angeles📍 Los Angeles📍 Los Angeles Nammi Therapeutics Inc · Tests: QXL138AM Injection every 2 weeks by IV Infusion Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT NCT06664996Phase 21 site📍 Chengdu West China Hospital · Tests: stereotactic body radiation therapy (SBRT), Sintilimab (approved) Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) NCT06796803Phase 2, Phase 32 sites📍 Harbin📍 Shanghai Shanghai Zhongshan Hospital · Tests: camrelizumab combined with rivoceranib and HAIC, camerlizumab + rivoceranib HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma NCT06187961Phase 21 site📍 Wuhan Tongji Hospital · Tests: Hepatic arterial infusion chemotherapy (HAIC-FOLFOX), Lenvatinib, Cadonilimab Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases NCT05248581n/a1 site📍 Rochester University of Rochester · Tests: Liver transplantation Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma NCT07014150Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Lenvatinib, Iparomlimab and Tuvonralimab Intravital Microscopy in Human Solid Tumors NCT03823144NA1 site📍 Jacksonville Mayo Clinic · Tests: Diagnostic Microscopy, Fluorescein Sodium Injection TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk NCT07487662Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: sintilimab, ipilimumab N01, Lenvatinib, TACE, ablation Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma. NCT07027436Phase 32 sites📍 Hamilton📍 London Hamilton Health Sciences Corporation · Tests: Chemotherapy/Radiation The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy NCT05035108EARLY Phase 11 site📍 Hangzhou Sir Run Run Shaw Hospital · Tests: hiHep bioartificial liver therapy Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) NCT06561399n/a4 sites📍 Fuzhou📍 Fuzhou📍 Fuzhou Fujian Provincial Hospital · Tests: TACE, Lenvatinib combination with Sintilimab sequential radiotherapy Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC NCT06904014Phase 21 site📍 Jinan Lei ZHAO · Tests: HAIC, Sintilimab, Lenvatinib, surgery Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC NCT07018947Phase 212 sites📍 Badalona📍 Barcelona📍 Barcelona Fundacion Clinic per a la Recerca Biomédica · Tests: Atezolizumab and Bevacizumab Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma NCT05713994n/a2 sites📍 Quanzhou📍 Wuhan Ze-yang Ding, MD · Tests: HAIC, Bevacizumab plus Atezolizumab, Bevacizumab Biosimilar IBI305 plus sintilimab, Lenvatinib, Sorafenib Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC NCT05608200Phase 31 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy